We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02076139
Previous Study | Return to List | Next Study

Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02076139
First Posted: March 3, 2014
Last Update Posted: February 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Manresana de Micobacteriologia, SL
  Purpose
This is a double-blind, masked, compared with placebo clinical trial in healthy volunteers with or without tuberculosis infection. This trial aims to study the effect of the probiotic Nyaditum resae® at the level of specific Regulatory T cells (Treg) memory cells one week after the first administration and the global tolerability of the treatment. Nyaditum resae® is a preparation in the form of drinkable vials containing heat-killed environmental mycobacteria. The overall objective of the study is the effect of Nyaditum resae® on immunity, which could reduce the risk of developing active tuberculosis.

Condition Intervention
Tuberculosis Dietary Supplement: Nyaditum resae® 10e4 Dietary Supplement: Nyaditum resae® 10e5 Other: Distilled water

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Pilot Clinical Trial, Double-blind, Randomized, Placebo Controlled and Masked to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae® Probiotic Administered to Adults With or Without Latent Tuberculosis Infection

Resource links provided by NLM:


Further study details as provided by Manresana de Micobacteriologia, SL:

Primary Outcome Measures:
  • Change from Baseline in Specific Treg memory cells at week 1 [ Time Frame: From Baseline to Week 1 ]
    Median increase of specific Treg memory cells at week 1.

  • Global tolerability of Nyaditum resae ®, proportion of participants with adverse events related to study treatment. [ Time Frame: Baseline to week 6 ]
    Proportion of patients presenting adverse events related to study treatment.


Secondary Outcome Measures:
  • Local tolerability (gastrointestinal duct), proportion of participants with gastrointestinal adverse events related to study treatment. [ Time Frame: Baseline to week 6 ]
    Proportion of participants presenting gastrointestinal adverse events related to study treatment.

  • Systemic tolerability (vital signs, physical exam, laboratory tests), proportion of participants with systemic adverse events related to study treatment. [ Time Frame: Baseline to week 6 ]
    Proportion of participants presenting systemic adverse events related to study treatment.

  • Change from Baseline in Specific Treg memory cells at week 2 [ Time Frame: From Baseline to Week 2 ]
    Median increase of specific Treg memory cells at week 2.

  • Change from Baseline in Specific Treg memory cells at month 12 [ Time Frame: From Baseline to Month 12 ]
    Median increase of specific Treg memory cells at month 12


Enrollment: 47
Study Start Date: March 2014
Study Completion Date: July 2015
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nyaditum resae® 10e4
The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e4 Colony-forming units (CFUs) of Nyaditum resae®.
Dietary Supplement: Nyaditum resae® 10e4
Experimental: Nyaditum resae® 10e5
The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e5 CFUs of Nyaditum resae®.
Dietary Supplement: Nyaditum resae® 10e5
Placebo Comparator: Placebo
The subjects will receive 1 drinkable vial (4mL) of distilled water per day during 14 days.
Other: Distilled water

Detailed Description:

The incidence of tuberculosis is still a problem of the first magnitude. Every year 1.5 million people die; there are 10 million cases of illness and 100 million new infected. The growing problem of multiresistance is to be added, remaining so prevalent: 700,000 patients, a figure that increases annually with 100,000 people. Prevention of tuberculosis is currently very difficult because it is a disease caused by a bacillus (Mycobacterium tuberculosis) that is transmitted by air: No risk factor for becoming infected has been identified and there is still no prophylactic vaccine that prevents from infection. One of the most characteristic aspects of tuberculosis is that the majority (90-95 %) of people without immunity alterations do not develop the disease after being infected. As for people who do develop the disease, it is still not known why they develop it.

A group of researchers from the Institut Germans Trias i Pujol recently discovered a mechanism that explains this trend. In short, what happens is that certain people create a too strong inflammatory response against tuberculosis bacillus, which ends up creating massive destruction of the tissue that is around the bacillus and brings the characteristic lesion of tuberculosis: tuberculous cavity.

This group of researchers was devising ways to "reeducate" the immune system against the bacillus not make it aggressive. And they did it using two instruments. The first one, an environmental mycobacteria, namely a bacillus of the family of mycobacteria tuberculosis, that usually lives in the water they drink, so that at a greater or lesser extent the investigators already have it in their intestinal flora. The second, inducing a tolerant response, like the investigators do when they eat food. To induce a tolerant response, low and repeated doses of the product make the immune system of the digestive duct "used to" their presence. Thus, when it becomes to find the product, the immune system reacts in a very light and balanced manner, avoiding excessive inflammatory responses. The clearest example is the fact that their immune system "is used" to feed proteins and generates no rejection answers found in the intestinal mucosa.

Hence comes the probiotic Nyaditum resae®, a preparation in the form of drinkable vials, containing a heat-killed environmental mycobacteria and thus can generate a cross-immunity with the tuberculosis bacillus. By giving low and repeated dose to generate a tolerant response, which happens when there is an infection by Mycobacterium tuberculosis, so that a balanced immune response is triggered able to reduce the risk of developing active tuberculosis.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Informed consent before starting the selection process.
  2. Women and men ≥ 18 years.
  3. Availability to meet the requirements of the protocol.

Exclusion Criteria:

  1. HIV positive.
  2. Known immunodeficiencies.
  3. Pregnancy and maternal lactation.
  4. Active tuberculosis.
  5. Enrollment in another clinical trial.
  6. Chronic administration of: methotrexate, azathioprine, cyclophosphamide, oral corticosteroids and other immunosuppressive therapies / immunomodulatory .
  7. Administration of blood products or blood derivatives during the 6 months prior to randomization.
  8. Detection by the researcher lack of knowledge or willingness to participate and fulfill all the requirements of the protocol.
  9. Any other finding that the investigator's opinion, could jeopardize the performance of the protocol or significantly influence the results or interpretation of the effects of probiotic.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02076139


Locations
Spain
Germans Trias I Pujol Hospital
Badalona, Barcelona, Spain, 08916
Sponsors and Collaborators
Manresana de Micobacteriologia, SL
Investigators
Principal Investigator: Eva Montané, MD, PhD Germans Trias i Pujol Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Manresana de Micobacteriologia, SL
ClinicalTrials.gov Identifier: NCT02076139     History of Changes
Other Study ID Numbers: NYADATREG
First Submitted: February 20, 2014
First Posted: March 3, 2014
Last Update Posted: February 23, 2017
Last Verified: February 2017

Keywords provided by Manresana de Micobacteriologia, SL:
tuberculosis
treg
tolerance
probiotic
mycobacteria

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections